{"disease":{"id":"lysosomal-acid-lipase-deficiency","name":"lysosomal acid lipase deficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT07455864","title":"Lysosomal Acid Lipase Deficiency in Risk Groups","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03984149","title":"Lipa Gene Mutation in PED-LIPIGEN (Pediatric FH Subjects)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)","has_results":false},{"nct_id":"NCT01633489","title":"Lysosomal Acid Lipase (LAL) Deficiency Registry","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT01757184","title":"Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03564002","title":"Metabolic Effects of Very Low Carbohydrate Ketogenic Diet in Subjects With Severe Obesity","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT02112994","title":"Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02193867","title":"Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01371825","title":"Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01307098","title":"Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01488097","title":"Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02376751","title":"An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}